The Use of Topiramate for Weight Loss Causing Acute Glaucoma: A Case Report and Literature Review
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 8 No. 2 (2019),
15 June 2019
,
Page 116-120
Abstract
Topiramate is a sulfa-containing drug which is able to disrupt the ocular blood barrier. Recently it has gained more popularity, being used in many clinical conditions. Nowadays, the cases of glaucoma induced by topiramate have increased due to the use of this drug to induce weight loss. We here described a 29-year-old female presented with a one-day history of blurred vision in both eyes and headache. She was using a weight loss formula containing topiramate 100 milligrams. Ophthalmologic exam revealed an important myopic shift of -7.00 spherical diopters at presentation with intraocular pressure (IOP) of 32 mmHg and a shallow anterior chamber in both eyes. After discontinuous of topiramate and use of cycloplegic eyedrops, myopic shift improved and IOP controlled after two days. The anterior chamber was significantly deeper in both eyes after two weeks. It is theorized that topiramate can provoke a ciliochoroidal effusion and, therefore, can cause an anterior displacement of lens-iris diaphragm with a secondary angular closure. The treatment must include cycloplegic and discontinuation of the drug. Sulfa-containing drugs lead to an indirect mechanism of angle closure, frequently bilateral and, as mentioned above, with a different treatment approach. If unrecognized and untreated, it can provoke high morbidity with possibility of bilateral permanent visual loss.
References
Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711-20. doi: 10.1016/S0140-6736(04)16257-0 pmid: 15158634
Marvasti AH, Tatham AJ, Zangwill LM, Girkin CA, Liebmann JM, Weinreb RN, et al. The relationship between visual field index and estimated number of retinal ganglion cells in glaucoma. PLoS One. 2013;8(10):e76590. doi: 10.1371/journal.pone.0076590 pmid: 24146895
Razeghinejad MR, Pro MJ, Katz LJ. Non-steroidal drug-induced glaucoma. Eye (Lond). 2011;25(8):971-80. doi: 10.1038/eye.2011.128 pmid: 21637303
Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010;24(6):501-26. doi: 10.2165/11533180-000000000-00000 pmid: 20443647
Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol. 2001;132(1):112-4. doi: 10.1016/s0002-9394(01)01013-3
Grewal DS, Goldstein DA, Khatana AK, Tanna AP. Bilateral angle closure following use of a weight loss combination agent containing topiramate. J Glaucoma. 2015;24(5):e132-6. doi: 10.1097/IJG.0000000000000157 pmid: 25304279
Cereza G, Pedros C, Garcia N, Laporte JR. Topiramate in non-approved indications and acute myopia or angle closure glaucoma. Br J Clin Pharmacol. 2005;60(5):578-9. doi: 10.1111/j.1365-2125.2005.02470.x pmid: 16236051
Abtahi MA, Abtahi SH, Fazel F, Roomizadeh P, Etemadifar M, Jenab K, et al. Topiramate and the vision: a systematic review. Clin Ophthalmol. 2012;6:117-31. doi: 10.2147/OPTH.S27695 pmid: 22275816
Rodriguez-Gomez D, Castro-Perez A, Landaluce-Chaves ML, Cid-Rodriguez MC, Lustres-Perez M, Gomez-Fernandez RC. [Narrow-angle glaucoma and acute myopia from using topiramate as prophylactic treatment of migraine]. Rev Neurol. 2007;45(4):254. pmid: 17668412
Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol. 2004;137(1):193-5. pmid: 14700673
Ikeda N, Ikeda T, Nagata M, Mimura O. Ciliochoroidal effusion syndrome induced by sulfa derivatives. Arch Ophthalmol. 2002;120(12):1775. pmid: 12470170
Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology. 2004;111(1):109-11. doi: 10.1016/j.ophtha.2003.04.004 pmid: 14711721
van Issum C, Mavrakanas N, Schutz JS, Shaarawy T. Topiramate-induced acute bilateral angle closure and myopia: pathophysiology and treatment controversies. Eur J Ophthalmol. 2011;21(4):404-9. doi: 10.5301/EJO.2010.5979 pmid: 21058272
Symes RJ, Etminan M, Mikelberg FS. Risk of angle-closure glaucoma with bupropion and topiramate. JAMA Ophthalmol. 2015;133(10):1187-9. doi: 10.1001/jamaophthalmol.2015.2180 pmid: 26158444
Willett MC, Edward DP. Refractory topiramate-induced angle-closure glaucoma in a man: a case report. J Med Case Rep. 2011;5:33. doi: 10.1186/1752-1947-5-33 pmid: 21269432
Rhee DJ, Ramos-Esteban JC, Nipper KS. Rapid resolution of topiramate-induced angle-closure glaucoma with methylprednisolone and mannitol. Am J Ophthalmol. 2006;141(6):1133-4. doi: 10.1016/j.ajo.2006.01.021 pmid: 16765687
Diaz-Cespedes RA, Toro-Giraldo D, Olate-Perez A, Hervas-Ontiveros A, Garcia-Delpech S, Udaondo-Mirete P. Contribution of the Visante((R)) OCT and B-scan ultrasound in the diagnosis and follow up of a topiramate-induced bilateral ciliochoroidal effusion syndrome. Arch Soc Esp Oftalmol. 2019. doi: 10.1016/j.oftal.2019.01.004 pmid: 30738599
Mitra A, Ramakrishnan R, Kader MA. Anterior segment optical coherence tomography documentation of a case of topiramate induced acute angle closure. Indian J Ophthalmol. 2014;62(5):619-22. doi: 10.4103/0301-4738.129784 pmid: 24881612
Saffra N, Smith SN, Seidman CJ. Topiramate-induced refractive change and angle closure glaucoma and its ultrasound bimicroscopy findings. BMJ Case Rep. 2012;2012. doi: 10.1136/bcr-2012-006509 pmid: 22859383
Natesh S, Rajashekhara SK, Rao AS, Shetty B. Topiramate-induced angle closure with acute myopia, macular striae. Oman J Ophthalmol. 2010;3(1):26-8. doi: 10.4103/0974-620X.60018 pmid: 20606870
Mahendradas P, Parab S, Sasikumar R, Kawali A, Shetty BK. Topiramate-induced acute angle closure with severe panuveitis: A challenging case report. Indian J Ophthalmol. 2018;66(9):1342-4. doi: 10.4103/ijo.IJO_1192_17 pmid: 30127167
Osaba M, Reviglio VE. Case report: the role of OCT in examination of a patient with topiramate-induced acute angle closure, acute myopia and macular striae. Oxf Med Case Reports. 2018;2018(7):omy030. doi: 10.1093/omcr/omy030 pmid: 30094042
Mazumdar S, Tripathy K, Sarma B, Agarwal N. Acquired myopia followed by acquired hyperopia due to serous neurosensory retinal detachment following topiramate intake. Eur J Ophthalmol. 2019;29(1):NP21-NP4. doi: 10.1177/1120672118797286 pmid: 30175623
Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Inflamm. 2011;19(1):86-8. doi: 10.3109/09273948.2010.523805 pmid: 21034312
Rapoport Y, Benegas N, Kuchtey RW, Joos KM. Acute myopia and angle closure glaucoma from topiramate in a seven-year-old: a case report and review of the literature. BMC Pediatr. 2014;14:96. doi: 10.1186/1471-2431-14-96 pmid: 24712825
Lan YW, Hsieh JW. Bilateral acute angle closure glaucoma and myopic shift by topiramate-induced ciliochoroidal effusion: case report and literature review. Int Ophthalmol. 2018;38(6):2639-48. doi: 10.1007/s10792-017-0740-y pmid: 29063980
Caglar C, Yasar T, Ceyhan D. Topiramate induced bilateral angle-closure glaucoma: low dosage in a short time. J Ocul Pharmacol Ther. 2012;28(2):205-7. doi: 10.1089/jop.2011.0161 pmid: 22149720
Czyz CN, Clark CM, Justice JD, Pokabla MJ, Weber PA. Delayed topiramate-induced bilateral angle-closure glaucoma. J Glaucoma. 2014;23(8):577-8. doi: 10.1097/IJG.0b013e3182948491 pmid: 23632405
- Abstract Viewed: 1036 times
- Free Full Text PDF Downloaded: 722 times
